✦ LIBER ✦

Receptor- and signal transductionrelated proto-oncogenes in breast cancer

✍ Scribed by Robert B. Dickson; Neil Rosen; Edward P. Gelmann; Marc E. Lippman

Book ID: 119111975
Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 737 KB
Volume: 8
Category: Article
ISSN: 0165-6147
DOI: 10.1016/0165-6147(87)90094-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Proto-oncogene mutations in human breast

Proto-oncogene mutations in human breast cancer (HBC)

✍ A. Ezzat; A. Abdul El-Warith; M.A. Ali; A.M. Abdulkareem; M. Senoussi; T. Amin; 📂 Article 📅 1991 🏛 Elsevier Science ⚖ 179 KB

Genetic variability of proto-oncogenes f

Genetic variability of proto-oncogenes for breast cancer risk and prognosis

✍ Lidereau, Rosette; Mathieu-Mahul, Danièle; Escot, Chantale; Theillet, Charles; C 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 867 KB

Altered Ca2+ signaling in cancer cells:

Altered Ca2+ signaling in cancer cells: Proto-oncogenes and tumor suppressors targeting IP3 receptors

✍ Akl, Haidar; Bultynck, Geert 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 668 KB

Studies of the HER-2/neu Proto-Oncogene

Studies of the HER-2/neu Proto-Oncogene in Human Breast Cancer

✍ Dennis J. Slamon; William Godolphin; Axel Ullrich; Michael F. Press 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Proto-oncogene amplification and HSRs in

Proto-oncogene amplification and HSRs in human breast carcinomas.

✍ C. Saint-Ruf; M. Gerbault-Seureau; B. Malfoy; E. Viegas-Pequignot; B. Zafrani; B 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Expression and loss of heterozygosity of

Expression and loss of heterozygosity of c-met proto-oncogene in primary breast cancer

✍ Dr. Janos Nagy; James S. Clark; Alexander Cooke; Ailsa M. Campbell; James M. Con 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

## Abstract The c‐met proto‐oncogene encodes the receptor to hepatocyte growth factor‐scatter factor (HGF‐SF), a mesenchyme‐derived cytokine with cell‐dissociating, invasion, and angiogenic properties. The expression of c‐met in breast cancer is the subject of controversy; 111 primary breast cancer